ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agenți antitrombotici - prevenirea tromboembolismului venos (vte) la pacienții adulți supuși unei intervenții chirurgicale de înlocuire a șoldului sau a genunchiului. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 pentru haemodynamically instabil pe pacienți). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 și 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamentul trombozei venoase profunde (tvp) și embolie pulmonară (ep), și prevenirea tvp și ep recurente la adulți. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenți antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

lupin europe gmbh - mexiletine hydrochloride - miotonice tulburări - terapia cardiacă - namuscla este indicat pentru tratamentul simptomatic al miotonie la pacienții adulți cu non-distrofice miotonice tulburări.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

serb sa - amifampridine phosphate - lambert-eaton myasthenic syndrome; paraneoplastic syndromes, nervous system; nervous system neoplasms; paraneoplastic syndromes; nervous system diseases; autoimmune diseases of the nervous system; neurodegenerative diseases; neuromuscular diseases; neuromuscular junction diseases; immune system diseases; autoimmune diseases; autoimmune diseases of the nervous system; cancer; neoplasms - alte medicamente pentru sistemul nervos - tratamentul simptomatic al sindromului myasthenic lambert-eaton (lems) la adulți.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - terapia cu bila și cu ficatul - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 și 5.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresoare - consultați documentul cu informații despre produs.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

amneal pharma europe ltd - levodopa, carbidopa - boala parkinson - medicamente anti-parkinson - tratamentul simptomatic al pacienților adulți cu boală parkinson.

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

axunio pharma gmbh - pirfenidonă - fibroza pulmonară idiopatică - imunosupresoare - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

viatris limited - pirfenidonă - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresoare - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

eco animal health europe limited - tilvalosin - antiinfectioase de uz sistemic, antibacteriene pentru uz sistemic, macrolide - pheasants; chicken; turkeys; pigs - pigstreatment și methaphylaxis pneumoniei enzootice porcine;tratamentul enteropatiei proliferative porcine (ileita);tratament și methaphylaxis dizenteriei porcine. chickenstreatment și methaphylaxis bolilor respiratorii asociate cu mycoplasma gallisepticum la puii de găină. pheasantstreatment bolilor respiratorii asociate cu mycoplasma gallisepticum. turkeystreatment bolilor respiratorii asociate cu tartratul de tulpini sensibile de ornithobacterium rhinotracheale la curcani.